MBX Biosciences doses first participant in Phase 1 trial of MBX 4291

MBX Biosciences (MBX) announced dosing of the first participant in its Phase 1 trial of MBX 4291, the Company’s Precision Endocrine Peptide, PEP, glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide co-agonist prodrug candidate for the treatment of obesity. “Initiation of our first clinical trial in obesity is a significant milestone for the Company and an important step in addressing this global public health issue,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “MBX 4291 has demonstrated positive preclinical results and is designed to be a best-in-class weight loss prodrug, with the potential for convenient once-monthly administration, improved weight loss, and better gastrointestinal tolerability compared to currently available treatment options. We look forward to topline results anticipated in 2027.”